Completion Of A Successful University Study Of BioAgra's Product Agrastim(R) For Replacement Of Antibiotics In Poultry Feed

Main Category: Water - Air Quality / Agriculture
Also Included In: Veterinary
Article Date: 11 Aug 2007 - 1:00 PDT

email to a friend   printer friendly   view / write opinions   rate article

Vyta Corp (OTCBB: VYTC) and Justin Holdings, Inc., equal owners of their joint venture, BioAgra, LLC, announced the completion of a successful university study of its product Agrastim(R), a purified yeast beta-1,3/1,6-D glucan product with an 80% or greater biological activity.

This study was conducted at the University of Georgia, Athens, GA, in collaboration with the Southern Poultry Research Institute under the direction of Dr. Charles Hofacre and Mr. Greg Mathis, Ph.D., President of Southern Poultry Research Institute. Dr. Hofacre is considered the foremost authority on necrotic enteritis by the poultry industry and the scientific community. The study was designed to demonstrate that Agrastim(R) can safely and effectively replace antibiotics in the feed of broilers when challenged by Clostridium perfringens, the agent that causes necrotic enteritis.

Necrotic enteritis is a disease that causes significant losses in the broiler industry. Once the disease is identified, the flock is usually treated with antibiotics, to reduce mortality and economic loss. Since the marketplace now is demanding antibiotic-free chickens, it has become necessary for the poultry industry to find new non-antibiotic means to prevent and/or limit the occurrence of necrotic enteritis and other diseases.

This study supports BioAgra's claim that Agrastim(R) is able to safely and economically replace antibiotics in poultry feeds even in the presence of infectious agents. BioAgra expects that under conditions in which subclinical infections are present, Agrastim(R) may perform even better than antibiotics. Agrastim(R) can be used in the feed stock of all living organisms and directly activates both the innate and adaptive immune systems.

About Vyta Corp:

Vyta Corp of Denver, Colorado, is traded on the over-the-counter NASDAQ stock market (OTCBB: VYTC) as well as on the Frankfurt, Hamburg, XETRA and Munich Exchanges (OTC: VYTA).

Vyta Corp owns a 50% interest in BioAgra, LLC, a joint venture to manufacture and sell Agrastim(R), a purified yeast beta-1,3/1,6-D glucan product with a high bioactivity level of 80% or greater.

In addition to the 12 patents it owns, Vyta Corp has applications pending and various intellectual properties related to NCS(TM) (NanoPierce Connection System). This advanced system is designed to provide significant improvement over conventional electrical and mechanical interconnection methods for high density circuit boards, components, sockets, connectors, semiconductor packaging and electronic systems. It also owns a 49% interest in ExypnoTech GmbH, a Germany-based manufacturer of smart inlays which are used in RFID identification devices such as smart labels, smart tags and smart cards. For more information on Vyta Corp and its business partners, please visit the websites: http://www.vytacorp.com or http://www.exypnotech.com.

About BioAgra, LLC:

BioAgra, LLC is based in Hinesville, Georgia where it produces, markets and sells Agrastim(R), which is a purified yeast beta-1,3/1,6-D glucan product with a high bioactivity function that improves the immune systems of animals and humans. Agrastim(R) is an all-natural, organic, non-toxic natural beta glucan feed supplement derived from spent brewer's and distillery yeast. It is also used to replace fast growth promotion antibiotics that are currently used in the feed of the livestock, swine, poultry, turkey, dairy, equine, aqua-culture and other industries. For more information on BioAgra, LLC, please visit its website at: http://www.bioagra.net.

This announcement contains forward-looking statements about Vyta Corp that may involve risks and uncertainties. Important factors relating to the Company's operations could cause results to differ materially from those in forward-looking statements and further detailed in filings with the Securities and Exchange Commission (SEC) available at the SEC website (http://www.sec.gov). All forward-looking statements are based on information available to Vyta Corp on the date hereof and Vyta Corp assumes no obligation to update such statements.

http://www.bioagra.net